Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
plegridy
Synonyms :
peginterferon beta-1a
Class :
immunomodulator
Brand Name :
plegridy
Synonyms :
peginterferon beta-1a
Class :
immunomodulator
Dosage Forms & StrengthsÂ
Prefilled Subcutaneous injectable solutionÂ
63mcg/0.5ml and 94mcg/0.5mlÂ
125mcg/0.5mlÂ
Day 1:63mcg subcutaneous or intramuscular
Day 15:94mcg subcutaneous or intramuscular
From day 29: 125mcg subcutaneous or intramuscular once and every 14 days
Dosage Forms & StrengthsÂ
Safety and efficacy not establishedÂ
Insufficient data availableÂ
may increase the toxic effect
may increase the toxic effect
It may diminish the therapeutic efficacy when combined with pegloticase
may enhance the adverse/toxic effect of interferons
Frequency defined:Â Â
>10%Â
SubcutaneousÂ
Influenza-like illnessÂ
HeadacheÂ
Pain at the injection siteÂ
Pruritis injection siteÂ
Erythema injection siteÂ
PyrexiaÂ
ChillsÂ
AstheniaÂ
IntramuscularÂ
HeadacheÂ
Pain at the injection siteÂ
ChillsÂ
PainÂ
1-10%Â
SubcutaneousÂ
Increased ASTÂ
Increased ALTÂ
HyperthermiaÂ
Edema at the injection siteÂ
Hematoma at the injection siteÂ
Warmth at the injection siteÂ
rash at the injection siteÂ
Post-marketing reportsÂ
Non-infectious hepatitisÂ
AnaphylaxisÂ
Necrosis at the injection siteÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: peginterferon beta-1aÂ
Pronounced: [ peg-in-ter-FEAR-on-BAY-ta-1A ]Â
Why do we use peginterferon beta-1a?Â
Peginterferon beta-1a is a medication used to treat relapsing forms of multiple sclerosis (MS). It is a modified form of interferon beta-1a, a protein produced naturally by the body to help fight viral infections and other diseases. Peginterferon beta-1a works by modifying the immune system’s response to the body’s tissues, which can help reduce inflammation and damage to the central nervous system. It is usually given as an injection under the skin or into a muscle and is typically used with other MS medicationsÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
